The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
S-1 plus oxaliplatin compared with fluorouracil/leucovorin/oxaliplatin as neoadjuvant chemotherapy for locally advanced gastric carcinoma.
Jiren Yu
No relevant relationships to disclose
Yijun Wu
No relevant relationships to disclose
Yuan Gao
No relevant relationships to disclose
Qianyun Shen
No relevant relationships to disclose
Qing Zhang
No relevant relationships to disclose
Xiaosun Liu
No relevant relationships to disclose
Kankai Zhu
No relevant relationships to disclose